Cargando…

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Wang, Kun, Yu, Albert, Liu, Kewei, Feng, Chunyan, Hou, Yibo, Chen, Jiawei, Ma, Shaohua, Huang, Laiqiang, Dai, Xiaoyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502625/ https://www.ncbi.nlm.nih.gov/pubmed/37712353 http://dx.doi.org/10.1002/advs.202305364

Ejemplares similares

Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
por: Wang, Kun, et al.
Publicado: (2023)

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
por: Ahn, Green, et al.
Publicado: (2021)

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
por: Alabi, Shanique B., et al.
Publicado: (2021)

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
por: Wang, Kun, et al.
Publicado: (2022)

IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins
por: Mikitiuk, Michał, et al.
Publicado: (2023)

Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10
por: Yin, Shan-Shan, et al.
Publicado: (2020)

CD24-Siglec interactions in inflammatory diseases
por: Liu, Yang, et al.
Publicado: (2023)

FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma
por: Hou, Yibo, et al.
Publicado: (2023)

A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer
por: Deng, Ting, et al.
Publicado: (2023)

CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy
por: Barkal, Amira A, et al.
Publicado: (2019)

Molecular cloning of porcine Siglec-3, Siglec-5 and Siglec-10, and identification of Siglec-10 as an alternative receptor for porcine reproductive and respiratory syndrome virus (PRRSV)
por: Xie, Jiexiong, et al.
Publicado: (2017)

Preferential use of Siglec-1 or Siglec-10 by type 1 and type 2 PRRSV strains to infect PK15(S1–CD163) and PK15(S10–CD163) cells
por: Xie, Jiexiong, et al.
Publicado: (2018)

Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10
por: Forgione, Rosa Ester, et al.
Publicado: (2020)

Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10
por: Forgione, Rosa Ester, et al.
Publicado: (2020)

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy
por: Liu, Yuhong, et al.
Publicado: (2022)

Siglec Ligands
por: Gonzalez-Gil, Anabel, et al.
Publicado: (2021)

Common determinants of severe Covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related Siglecs, Siglec-3 and Siglec-5/14
por: Murch, Simon H.
Publicado: (2020)

Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas
por: Wang, Hesong, et al.
Publicado: (2022)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
por: Hernández-Caselles, Trinidad, et al.
Publicado: (2019)

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
por: Li, Song, et al.
Publicado: (2023)

Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
por: Hayakawa, Toshiyuki, et al.
Publicado: (2017)

Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease
por: Herzog, Silva, et al.
Publicado: (2022)

Plasma Siglec-5 and CD163 as Novel Biomarkers for Fulminant Myocarditis
por: Zhuang, Yan, et al.
Publicado: (2022)

Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
por: Rodriguez, Ernesto, et al.
Publicado: (2021)

Siglecs at the Host–Pathogen Interface
por: Chang, Yung-Chi, et al.
Publicado: (2020)

Siglecs as Therapeutic Targets in Cancer
por: Lim, Jackwee, et al.
Publicado: (2021)

Siglec Signaling in the Tumor Microenvironment
por: van Houtum, Eline J. H., et al.
Publicado: (2021)

The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
por: Zheng, Yayun, et al.
Publicado: (2020)

CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function
por: Bandala-Sanchez, Esther, et al.
Publicado: (2018)

Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy
por: Yu, Albert, et al.
Publicado: (2022)

Correction: Yu et al. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109
por: Yu, Albert, et al.
Publicado: (2022)

Peripheral prion disease pathogenesis is unaltered in the absence of sialoadhesin (Siglec-1/CD169)
por: Bradford, Barry M, et al.
Publicado: (2014)

Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation
por: Hsu, Yaw-Wen, et al.
Publicado: (2021)

The prognostic impact of SIGLEC5-induced impairment of CD8(+) T cell activation in sepsis
por: Lozano-Rodríguez, Roberto, et al.
Publicado: (2023)

Siglec-G Deficiency Ameliorates Hyper-Inflammation and Immune Collapse in Sepsis via Regulating Src Activation
por: Li, Wenqian, et al.
Publicado: (2019)

Siglecs in Brain Function and Neurological Disorders
por: Siddiqui, Shoib Sarwar, et al.
Publicado: (2019)

Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022)

Mallotucin D, a Clerodane Diterpenoid from Croton crassifolius, Suppresses HepG2 Cell Growth via Inducing Autophagic Cell Death and Pyroptosis
por: Dai, Xiaoyong, et al.
Publicado: (2022)

Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression
por: Li, Yujuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9a9vvdi61h8fa2ns6ol0obukog